VISCHER assisted Inositec AG, a spin-off company of ETH Zurich having its registered seat in Zurich, in its seed financing round. Inositec develops drugs based on inositol hexaphosphate analogs for the treatment of vascular calcification and infections with Clostridium difficile, a highly resistant hospital germ. The CHF 1.4 million financing round included the Venture Incubator Fund and Zürcher Kantonalbank as well as further private investors. The VISCHER-Team was led by Matthias Staehelin (Partner) and Angelo Imperiale (Associate), both Corporate.